SCHEMBL6509041

SCHEMBL6509041

Cc1c2c(=O)n(CCCNC(=O)OC(C)(C)C)c3cc(I)ccc3c2nn1C1CCCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 4/20 0.42
DYRK1A Q13627 1/20 0.40
CNR2 P34972 1/20 0.37
PLK1 P53350 4/20 0.34
TDP1 Q9NUW8 1/20 0.34
BRD4 O60885 5/20 0.33
STING1 Q86WV6 1/20 0.33
ATRIP Q8WXE1 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
OPRK1 P41145 1/20 0.32
OGFRL1 Q5TC84 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6509760 0.94 ATR (0.42) ATRDYRK1ACNR2PLK1BRD4
SCHEMBL6522341 0.91 ATR (0.43) ATRDYRK1ACNR2PLK1TDP1
SCHEMBL6517473 0.91 ATR (0.42) ATRDYRK1ACNR2PLK1TDP1
SCHEMBL6513082 0.90 BRD4 (0.41) ATRDYRK1ACNR2PLK1TDP1
SCHEMBL6511027 0.87 ATR (0.42) ATRDYRK1ACNR2PLK1BRD4
SCHEMBL6512647 0.87 CNR2 (0.45) ATRDYRK1ACNR2PLK1BRD4
SCHEMBL6511907 0.87 ATR (0.42) ATRDYRK1ACNR2PLK1BRD4
SCHEMBL6521803 0.87 PLK1 (0.44) ATRDYRK1ACNR2PLK1BRD4
SCHEMBL6508889 0.87 ATR (0.42) ATRDYRK1ACNR2PLK1BRD4
SCHEMBL6518827 0.85 ATR (0.41) ATRDYRK1ACNR2PLK1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 ATR 717/4885DYRK1A 1079/4885CNR2 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.